(Reuters) – Japan’s Takeda Pharmaceutical Co Ltd <4502.T> said on Friday China’s market regulator had approved its $62 billion (47 billion pounds) acquisition of Shire Plc <SHP.L>, bringing it closer to becoming a global top 10 drugmaker.
The deal, which will be the largest overseas purchase by a Japanese company, has already received unconditional clearance from regulators in the United States and Brazil.
(Reporting by Shashwat Awasthi in Bengaluru; Editing by Sai Sachin Ravikumar)